At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Hemospan (MP4OX) +1 moredrug
Likely dose
Hemospan (MP4OX) 250 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia
In Brief
A Phase 2 clinical trial evaluating Hemospan (MP4OX) and Voluven (HES 130/0.4) for Vascular Disease and Critical Lower Limb Ischemia. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb ischemia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVascular Disease, Critical Lower Limb Ischemia
CountriesSweden
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedMar 2008
Primary CompletionJun 2008
Study CompletionDec 2008
TodayJul 2026
First PostedMar 12, 2008
Enrollment StartSep 1, 2007
Primary CompletionJun 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 18.3 years ago
Interventions
Hemospan (MP4OX)drug
250 mL of Hemospan (MP4OX)
Voluven (HES 130/0.4)drug
250 mL of Voluven (HES 130/0.4) solution